RBC Capital raised the firm’s price target on Pacira (PCRX) to $22 from $18 and keeps a Sector Perform rating on the shares. The company had an eventful quarter, highlighted by its conviction on Exparel strength for the foreseeable future, though it was slightly overshadowed by a deal for GQ Bio as the management shifts focus towards pipeline innovation, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira Pharmaceuticals: Strategic Initiatives and Financial Outlook Drive Buy Rating
- Pacira Pharmaceuticals: Undervalued with Strong Growth Potential and Legal Protections Against Generic Competition
- Pacira price target raised to $48 from $39 at H.C. Wainwright
- Pacira BioSciences Reports Record Revenue Amid Strategic Growth
- Pacira reports Q4 non-GAAP EPS 96c, consensus 83c